Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
authors Brumano, LP; da Silva, FVS; Costa-Silva, TA; Apolinario, AC; Santos, JHPM; Kleingesinds, EK; Monteiro, G; Rangel-Yagui, CD; Benyahia, B; Pessoa, A
nationality International
journal FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
author keywords L-asparaginase; quality-by-design; biobetters; protein engineering; PEGylation; nanobiotechnology; acute lymphoblastic leukemia; site-directed mutagenesis
keywords ACUTE LYMPHOBLASTIC-LEUKEMIA; ESCHERICHIA-COLI ASPARAGINASE; GLUTAMINASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ENZYME IMMOBILIZATION; THROMBIN GENERATION; PROTEIN-PRODUCTION; STANDARD-RISK; PLATE ASSAY; SCALE-UP
abstract L-Asparaginase (ASNase) is a vital component of the first line treatment of acute lymphoblastic leukemia (ALL), an aggressive type of blood cancer expected to afflict over 53,000 people worldwide by 2020. More recently, ASNase has also been shown to have potential for preventingmetastasis from solid tumors. The ASNase treatment is, however, characterized by a plethora of potential side effects, ranging from immune reactions to severe toxicity. Consequently, in accordance with Quality-by-Design (QbD) principles, ingenious new products tailored to minimize adverse reactions while increasing patient survival have been devised. In the following pages, the reader is invited for a brief discussion on the most recent developments in this field. Firstly, the review presents an outline of the recent improvements on the manufacturing and formulation processes, which can severely influence important aspects of the product quality profile, such as contamination, aggregation and enzymatic activity. Following, the most recent advances in protein engineering applied to the development of biobetter ASNases (i.e., with reduced glutaminase activity, proteolysis resistant and less immunogenic) using techniques such as site-directed mutagenesis, molecular dynamics, PEGylation, PASylation and bioconjugation are discussed. Afterwards, the attention is shifted toward nanomedicine including technologies such as encapsulation and immobilization, which aim at improving ASNase pharmacokinetics. Besides discussing the results of the most innovative and representative academic research, the review provides an overview of the products already available on the market or in the latest stages of development. With this, the review is intended to provide a solid background for the current product development and underpin the discussions on the target quality profile of future ASNase-based pharmaceuticals.
publisher FRONTIERS MEDIA SA
issn 2296-4185
year published 2019
volume 6
digital object identifier (doi) 10.3389/fbioe.2018.00212
web of science category Biotechnology & Applied Microbiology; Multidisciplinary Sciences
subject category Biotechnology & Applied Microbiology; Science & Technology - Other Topics
unique article identifier WOS:000455450400001
  ciceco authors
  impact metrics
journal analysis (jcr 2019):
journal impact factor 3.644
5 year journal impact factor Not Available
category normalized journal impact factor percentile 72.535
dimensions (citation analysis):
altmetrics (social interaction):



 


Sponsors

1suponsers_list_ciceco.jpg